

Dr. Fadlo Khuri Selected as Editor in Chief for **CANCER**

Succeeds Dr. Raphael E. Pollock

ATLANTA –August 1, 2011–Fadlo Khuri, M.D. has been selected as the new Editor-in-Chief for *Cancer*, a peer-reviewed journal of the American Cancer Society. Dr. Khuri will begin his term on September 1, 2011. He succeeds Dr. Raphael E. Pollock, who leaves the position after 11 years of service. Dr. Khuri has accepted a 5-year term for the editorship.

Dr. Khuri is Professor and Chair of Hematology and Medical Oncology at Emory University, the Deputy Director for the Winship Cancer Institute of Emory University, and Roberto C. Goizueta Distinguished Chair in Cancer Research. He has served as editor for the journal's lung section since 2005.

"It is a great privilege for me to serve as Editor-in-Chief of *Cancer*, succeeding my long-time friend and colleague, Dr. Raphael Pollock, who has done an outstanding job as Editor-in-Chief," said Dr. Khuri. "I received my first peer-reviewed grant from the American Cancer Society and published my first senior authored paper in *Cancer*. Given my long-standing relationship with both this exceptional journal and the ACS, this is a particularly meaningful honor for me. I will work hand-in-hand with *Cancer's* outstanding editorial staff, section editors, and editorial board to further accelerate the substantial progress of my predecessor. *Cancer* is one of the oncology community's oldest and most prestigious journals. We will work hard to enhance its already stellar and hard-earned reputation by seeking to publish only the very best work in the field."

"The Search Committee reviewed many exceptional candidates and is very pleased to have been able to select Dr. Khuri," said Otis W. Brawley, M.D., chief medical officer of the American Cancer Society. "As an accomplished molecular oncologist who has conducted seminal research on oncolytic viral therapy, and having led major chemoprevention efforts in lung and head and neck cancer. Dr. Khuri brings an expertise that will benefit our journal and the entire oncology community."

Dr. Khuri's clinical interests include thoracic and head and neck oncology. His research interests include development of molecular, prognostic, therapeutic, and chemopreventive approaches to improve the standard of care for patients with tobacco-related cancers. His laboratory is investigating the mechanism of action of signal transduction inhibitors in lung and aerodigestive track cancers.

He also serves as a grant reviewer for the American Cancer Society, National Cancer Institute, the American Association for Cancer Research, and the American Society of Clinical Oncology. He serves the National Cancer Institute as a permanent member of its Thoracic Malignancies Steering Committee and its Clinical Oncology Study Section, and serves on the Council for Extramural Funding of the American Cancer Society. He has published more than 200 peer-reviewed articles and has received numerous awards, including the Nagi Sahyoun Award from the Middle East Medical Assembly and the Waun Ki Hong Award from MD Anderson Cancer Center for his work on targeting signaling pathways in lung and aerodigestive cancers.

"We are excited to have Dr. Khuri on board. He has some great ideas around increasing *Cancer's* visibility and obtaining only the very best papers in the field. It is an exciting time for us," said Esmeralda Buchanan, Journals Director at the American Cancer Society for the last 11 years.

